• ZUPLENZ® is the First and Only 5-HT3 Receptor Antagonist available in an Oral Soluble Film
  • ZUPLENZ® FEATURES – Convenient Dosing, Dissolves Rapidly, Can be taken with or without water.
  • ZUPLENZ® (ondansetron oral soluble film) is indicated for the prevention of postoperative,highly and moderately emetogenic cancer chemotherapy-induced, and radiotherapy-induced nausea and vomiting.
  • Ondansetron U.S. market has maintained 10% growth year over year for last five years.*
  • Millions of prescriptions have been generated for ondansetron products since its launch in 1992.
  • Praelia’s sales force commenced sales activity in Dec 2012.
  • Product is now available for shipping.
  • Praelia’s sales force of 100+ skilled reps are targeting high decile Oncology supportive care physicians in all of the National Metro areas.
  • Praelia will utilize a tele sales team to e-detail the physicians in the surrounding Metro areas nationally.
  • Praelia is committed to working closely with Managed Care partners to maximize reimbursement.
  • Praelia is utilizing a discount copay card to reduce patient out of pocket cost.
  • Praelia Pharmaceuticals has dedicated a vast amount of resources towards introducing Zuplenz.
  • Ten (10) films per box.

NDC 4328810410                                                                                                   NDC 4328810810

Please see accompanying full prescribing information.
(*) based on IMS data

This entry was posted in Capital News, Weekly Specials. Bookmark the permalink.

Comments are closed.